OverviewChartNewsTraderScreen

Advaxis/  US0076243072  /

NASDAQ
2021-12-22  12:00:00 AM Chg. - Volume Bid12:00:00 AM Ask12:00:00 AM High Low
0.2400USD - 16.31 mill.
Turnover: -		 0.1700Bid Size: - 0.1701Ask Size: - 0.2902 0.2356
GlobeNewswire 02-20 Ayala Pharmaceuticals Announces Completion of Enrollment in Phase 3 RINGSIDE Study Evaluating AL102 ...
GlobeNewswire 2023-11-06 Ayala Pharmaceuticals Announces AL102 Receives Orphan Drug Designation for Desmoid Tumors
GlobeNewswire 2023-10-23 Ayala Pharmaceuticals Presents Updated AL102 Results from Phase 2 Clinical Trial in Desmoid Tumors a...
GlobeNewswire 2023-10-19 Ayala Pharmaceuticals Announces Closing of Merger with Biosight
GlobeNewswire 2022-03-22 Phathom Pharmaceuticals Announces Appointment of Molly Henderson as Chief Financial and Business Off...
GlobeNewswire 2022-03-17 Advaxis Reports First Quarter Ended January 31, 2022 Financial Results and Provides a Business Updat...
GlobeNewswire 2022-02-14 Advaxis Reports Fiscal Year 2021 Financial Results and Provides a Business Update
GlobeNewswire 2022-02-08 Delisting of Securities of China XD Plastics Company Limited and Advaxis, Inc. from The Nasdaq Stock...
GlobeNewswire 2022-01-28 Advaxis Prices Offering of $5,000,000 of Convertible Redeemable Preferred Stock Through a Private Pl...
GlobeNewswire 2022-01-11 Advaxis Presents Updated Clinical Data from Ongoing Phase 1/2 Trial of ADXS-503 in NSCLC and Upcomin...
GlobeNewswire 2021-12-22 Advaxis Announces Acceptance for Trading on the OTCQX
GlobeNewswire 2021-12-17 Advaxis to Continue to Explore Additional Options to Maximize Stockholder Value
GlobeNewswire 2021-12-09 Advaxis Issues Letter to Stockholders Regarding Recent Special Meeting Results
GlobeNewswire 2021-11-24 Advaxis Issues Letter and Second Video Message to Stockholders Regarding Upcoming Special Meeting
GlobeNewswire 2021-11-22 Nasdaq Grants Advaxis, Inc. an Extension to December 20, 2021, to Complete Merger Transaction with B...
GlobeNewswire 2021-11-19 Advaxis, Inc. Issues Letter to Stockholders
GlobeNewswire 2021-11-18 Leading Independent Proxy Advisory Firm Glass Lewis Joins ISS in Recommending Advaxis Stockholders V...
GlobeNewswire 2021-11-12 Biosight Announces Initiation of Phase 2 Clinical Trial of Aspacytarabine for MDS and AML
GlobeNewswire 2021-11-11 Biosight Encourages Advaxis Stockholders to Vote “FOR” Proposed Merger
GlobeNewswire 2021-11-04 Advaxis Issues Letter and Video Message to Stockholders Regarding Upcoming Special Meeting
GlobeNewswire 2021-11-03 Leading Independent Proxy Advisory Firm ISS Recommends Advaxis Stockholders Vote “FOR” the Merger wi...
GlobeNewswire 2021-10-06 aTyr Pharma Announces Appointment of Robert W. Ashworth, PhD, as Vice President of Regulatory Affair...
GlobeNewswire 2021-09-21 Arbutus Appoints Lisa M. Caperelli as Vice President, Investor Relations
GlobeNewswire 2021-09-10 Advaxis Reports 3rd Quarter Ended July 31, 2021 Financial Results and Provides a Business Update
GlobeNewswire 2021-08-11 Nasdaq Grants Advaxis, Inc. an Extension to November 22, 2021, to Regain Compliance with the $1.00 ...